Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort
Research output: Journal contributions › Journal articles › Research
Standard
Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort. / Moock, Joern; Friedrich, Nele; Völzke, Henry et al.
In: Growth Hormone and IGF Research, Vol. 21, No. 5, 01.10.2011, p. 272-278.Research output: Journal contributions › Journal articles › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort
AU - Moock, Joern
AU - Friedrich, Nele
AU - Völzke, Henry
AU - Spielhagen, Christin
AU - Nauck, Matthias
AU - Koltowska-Häggström, Maria
AU - Buchfelder, Michael
AU - Wallaschofski, Henri
AU - Kohlmann, Thomas
N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment. Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database). Results: The overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment. Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.
AB - Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment. Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database). Results: The overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment. Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.
KW - Health sciences
KW - Quality of life
KW - growth hormone dificiency
KW - normative reference values
KW - quantile regression
UR - http://www.scopus.com/inward/record.url?scp=80052572912&partnerID=8YFLogxK
U2 - 10.1016/j.ghir.2011.07.005
DO - 10.1016/j.ghir.2011.07.005
M3 - Journal articles
C2 - 21865066
VL - 21
SP - 272
EP - 278
JO - Growth Hormone and IGF Research
JF - Growth Hormone and IGF Research
SN - 1096-6374
IS - 5
ER -